SECOND INTERNATIONAL CONGRESS
ON TREATMENT OF DYSTONIA

SATELLITE EVENT
FIRST INTERNATIONAL CONFERENCE
ON REHABILITATION OF DYSTONIA

2013

HANNOVER - GERMANY






Preliminary Program and Call for Abstracts

May 8th – 11th, 2013
Hannover Congress Centrum

What could excellence in medicine look like?

A heritage built upon helping protect and preserve vision.

A commitment to advancing medical aesthetics.

A solution to help fight obesity.

A desire to help people move more freely.

A dedication to enabling people to live life without compromise and to their fullest potential.

It would look like Allergan.

Founded in 1950, Allergan, Inc., with headquarters in Irvine, California, is a multi-specialty healthcare company that discovers, develops and commercialises innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential.

To find out more about Allergan, visit www.allergan.co.uk



ALLERGAN

Our pursuit. Life's potential.®

Copyright 2011 Allergan, Inc. Irvine, UK 0363 2011.
® and ™ marks owned by Allergan, Inc.
EU/0015/2013a Date of Preparation: January 2013

Table of Content

Invitation 5

General Information. 7

Scientific Organisers. 9

Scientific Program 10



Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

The first and only botulinum neurotoxin product free from complexing proteins[1]:

- High sustained long-term efficacy leading to high patient satisfaction[2,3]
- Engineered for convenience and cost-effectiveness
  - Unopened XEOMIN® vials do not require refrigeration[1]
  - XEOMIN® is proven to be cost-effective in patients with cervical dystonia and blepharospasm[4]

XEOMIN® Botulinum neurotoxin type A
Free from complexing proteins

XEOMIN® is indicated for the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults. For full information please refer to the XEOMIN® SmPC.[1]

References: 1. XEOMIN® 50 U Summary of Product Characteristics. September 2012 (UK version). **2.** Evidente et al. Neurology 2011; 76 (9 Suppl 4): A540–A541 and Fernandez et al. Neurology 2011; 76 (9 Suppl 4): A330 **3.** Truong et al. Abstract presented at the 4th World Congress on Controversies in Neurology, 2010; Barcelona, Spain. html://www.comtecmed.com/cony/2010/uploads/assets/truong.pdf. **4.** Chadda et al. EJHP Practice. 2009; 15(6): 38–46.

XEOMIN®, 50 LD_{50} units or 100 LD_{50} units, Powder for solution for injection. **Active substance:** Clostridium Botulinum neurotoxin type A (150 kD; purified from cultures of Clostridium Botulinum (Hall strain)), free from complexing proteins. Prescription-only medicine! **Qualitative and quantitative composition:** One vial contains: Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins, 50 LD_{50} units or 100 LD_{50} units, Human albumin, Sucrose. (Due to unit differences in the LD_{50} assay, XEOMIN® units are specific to XEOMIN®. Therefore unit doses recommended for XEOMIN® are not interchangeable with those for other preparations of Botulinum toxin.) **Therapeutic indications:** For the symptomatic treatment of blepharospasm, cervical dystonia of a predominantly rotational form (spasmodic torticollis) and of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults. **Contraindications:** Hypersensitivity to Botulinum neurotoxin type A or to any of the excipients, generalised disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome). Presence of infection at the proposed injection site. **Undesirable effects:** May occur from misplaced injections or large doses of Botulinum neurotoxin type A that temporarily paralyse nearby muscle groups or muscles distant from the injection site. Usually, undesirable effects are observed within the first week after treatment and are temporary in nature. Restriction to the area around the injection site (e.g. local pain, tenderness at the injection site, and injection site haemorrhage) is possible. Localized pain, inflammation, paraesthesia, hypoesthesia, tenderness, swelling/oedema, erythema, localized infection bleeding and/or bruising may be associated with the injection. Needle-related pain and/or anxiety may result in vasovagal responses, including transient symptomatic hypotension and syncope. ***Blepharospasm*** Undesirable effects (XEOMIN®): *Common (≥1/100, <1/10)*: ptosis, dry eyes. *Uncommon (≥1/1,000, <1/100)*: paraesthesia, headache, conjunctivitis, dry mouth, skin rash, muscle weakness, inflicted injury. ***Spasmodic torticollis*** Undesirable effects (XEOMIN®): *Common (≥1/100, <1/10)*: dysphagia, muscle weakness, back pain. *Uncommon (≥1/1,000, <1/100)*: headache, tremor, eye pain, dysphonia, diarrhoea, dry mouth, vomiting, colitis, skin rash, erythema, pruritus, sweating increased, skeletal pain, myalgia, asthenia, injection site inflammation, injection site tenderness. Dysphagia with varying degrees of severity with the potential for aspiration may require medical intervention. Dysphagia may persist for two to three weeks after injection, but has been reported in one case to last five months. Dysphagia appears to be dose-dependent. Reports from clinical trials with Botulinum toxin type A complex that dysphagia occurs less frequently with total doses below 200 U per treatment session. ***Post-stroke spasticity of the upper limb*** Undesirable effects (XEOMIN®): *Common (≥1/100, <1/10)*: muscular weakness, injection site pain, injection site haematoma. *Uncommon (≥1/1,000, <1/100)*: dysaesthesia, headache, hypoaesthesia, haematoma, cough, dysphagia, nausea, dry mouth, erythema, pain in extremity, joint swelling, myalgia, feeling hot, asthenia, oedema peripheral. Some of these undesirable effects may be disease related. **Post-Marketing Experience:** Flu-like symptoms and hypersensitivity reactions like swelling, oedema (also apart from injection site), erythema, pruritus, rash (local and generalized) and breathlessness have been reported. ***General:*** The following additional information is also based on publications on conventional preparations containing Botulinum toxin type A complex: undesirable effects related to spread of toxin distant from the site of administration have been reported very rarely (exaggerated muscle weakness, dysphagia, and aspiration pneumonitis with fatal outcome in some cases). Dysphagia has been reported following injection to sites other than the cervical musculature. For further undesirable effects, also based on publications on conventional preparations containing Botulinum toxin type A complex: see Summary of Product Characteristics.

Merz Pharmaceuticals GmbH, 60318 Frankfurt/Main, Germany. Date of revision of the text: August 2012
Further information is provided in the Summary of Product Characteristics and in the Package Leaflet.
Phone: ++49-69/1503-1

MERZ

Invitation

Dear Colleagues,

Dystonias are amongst the most common movement disorders. Botulinum toxin and deep brain stimulation have revolutionized their therapy. However, there are still considerable unmet therapeutical needs.

This was the reason to organise the First International Congress on Treatment of Dystonia in the year 2010. The response was overwhelming: More than 450 participants from over 45 countries came to Hannover for an intense 3 day program.

With this encouragement we are now calling for the second congress of this series. With 3 years in between we believe there is now ample new data to discuss.

For the first time we are able to reach out to rehabilitation: The First International Conference on Rehabilitation of Dystonia will be incorporated as a pre-meeting satellite event.

We hope that this meeting will continue to serve as an open platform for all of us who want to collaborate for improving the future of patients with dystonias.

We are looking forward to welcoming you in Hannover in May 2013!

Best regards,

Eckart Altenmüller

Dirk Dressler

Joachim K. Krauss

Medtronic

Medtronic DBS Symposium

Shaping the future of Dystonia

How are 10 years of research and innovation leading us to the next level

Date: May 11th, 2013
Location: Hannover Congress Centrum (HCC)
Timing: 13:00 to 13:45



Innovating for life.

General Information

Congress Organisation
INTERPLAN Congress, Meeting & Event Management AG
Office Hamburg
Kaiser-Wilhelm-Str. 93
D-20355 Hamburg, Germany
Phone: +49 (0) 40 3250 9230
Fax: +49 (0) 40 3250 9244
E-mail: dystonia2013@interplan.de

Congress Venue
Hannover Congress Centrum (HCC)
Theodor-Heuss-Platz 1 – 3
D-30175 Hannover
Phone: +49 (0) 511 8113 0
Fax: +49 (0) 511 8113 429
E-mail: info@hcc.de

Congress Language
The official language of the Congress is English.

CME Certificate
An application has been submitted to the European Accreditation Council for Continuing Medical Education (EACCME) to provide accreditation for medical specialists. The CME Certificate will be supplied to participants on request.

Exhibition
An exhibition will be held during the Congress.

Abstract Submission
All participants of this congress are cordially invited to submit abstracts for oral presentations and / or poster presentations. Abstract acceptance will be notified from April 2nd, 2013.

Submission Deadline 18th March 2013
Please submit your abstract via this link:
www.abstractserver.de/hhdyst2013/absmgm

Registration Fees

	Early Registration until March 31, 2013	Late Registration from April 01, 2013
Conference fee (regular participants)	€ 440,00	€ 540,00
Conference fee (students*, allied health-care professionals)	€ 150,00	€ 250,00
Gala dinner**	Friday, May 10, 2013	€ 90,00

All prices are incl. 19% German VAT; in the name and for account of INTERPLAN AG.

* Student ID must be provided upon registration
** Tickets for the gala dinner are limited ("first come – first served") and are not included in the conference fee

IPSEN
Innovation for patient care

Scientific Organisers

Second International Congress on Treatment of Dystonia

Eckart Altenmüller, MD, MA
Professor of Neurology and Music Physiology
Director, Institute of Music Physiology
and Musicians' Medicine (IMMM)
Hannover University of Music, Drama and Media
Hannover, Germany

Dirk Dressler, MD
Professor of Neurology
Head of Movement Disorder Section
Department of Neurology
Hannover Medical School
Hannover, Germany

Joachim K. Krauss, MD
Professor of Neurosurgery
Chairman and Director
Department of Neurosurgery
Hannover Medical School
Hannover, Germany

Satellite Event

Theresa Jacobson Kimberley, PT
Associate Professor
University of Minnesota
Program in Physical Therapy
Program in Rehabilitation Science
Minneapolis, USA

Heidrun Pickenbrock, MSc, PT
Bobath-Instructor IBITA
LiN®-Trainer
Project Manager Spasticity
Movement Disorders Section
Department of Neurology
Hannover Medical School
Hannover, Germany

Lena Zetterberg, PT
Director of Studies of the Physical Therapy Program
Senior Lecturer
Uppsala University
Uppsala, Sweden

Endorsements

Interdisciplinary Working Group for Movement Disorders
International Association of Parkinsonism and Related Disorders
European Society for Stereotactic and Functional Neurosurgery

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Wednesday, May 8th 2013

13:15 – 18:00	**Satellite Event** **First International Conference on Rehabilitation of Dystonia** *Kimberley, Pickenbrock, Zetterberg*
13:15 – 13:30	Opening Remarks *Kimberley* *Pickenbrock* *Zetterberg* *Dressler*
13:30 – 14:00	Influence of Physical Therapy on Brain Activity *Kimberley*
14:00 – 14:30	Reviewing the Effects of Physical Therapy on Cervical Dystonia *Zetterberg*
14:30 – 15:00	Evidence based Treatment Strategies for Hand Dystonia *Byl*
15:00 – 15:30	Coffee Break
15:30 – 16:00	Clinical Perspectives of Physical Therapy for Cervical Dystonia and Hand Dystonia *Bleton*
16:00 – 16:30	Measuring Therapeutic Effects in Dystonia *Pickenbrock*
16:30 – 17:00	Linking Allied Health Care Professionals and Physicians: The IAB Model *Adib Saberi*
17:00 – 17:30	Panel Discussion: How to Integrate Physical Therapy into the Treatment of Dystonia *All*
17:30 – 18:00	Abstract Highlights *Kimberley* *Pickenbrock* *Zetterberg*

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Thursday, May 9th 2013

08:00 – 11:00	Workshops
08:00 – 09:30	Programming DBS for Treatment of Dystonia *Lütjens* *Schrader* *Kupsch*
08:00 – 09:30	Ultrasound Guidance for Botulinum Toxin Injections *Walter* *Tacik*
08:00 – 09:30	Current and Emerging Trends in Dystonia *Kimberley* *Pickenbrock*
08:00 – 09:30	Anatomy for Botulinum Toxin Injectors *Jog* *Chen*
09:30 – 11:00	Botulinum Toxin Therapy: Difficult Cases *Marion* *Truong* *Pirtosek*
09:30 – 11.00	Transcranial Electrophysiological Stimulation in Dystonia *Sommer* *Furuya*
09:30 – 11:00	Botulinum Toxin Therapy for Musician's Dystonias *Altenmüller* *Lee*
09:30 – 11:00	Behavioural Therapy *Boullet* *Zeuner*
09:30 – 11:00	Hands on or hands off: The best rehabilitation strategy for dystonia? *Pickenbrock* *Bleton*



Scientific Program

Thursday, May 9th 2013

11:30 – 12:00	**Opening Ceremony**
	Welcome Address by the Organisers *Altenmüller* *Dressler* *Krauss*
12:00 – 14:00	Lunch Break
12:15 – 13:45	**Lunch Symposium** **Allergan**
14:00 – 16:00	**Basics of Dystonia** *Albanese, Dengler*
14:00 – 14:20	Classification of Dystonias *Albanese*
14:20 – 14:40	Dystonia in Sports *Lobinger*
14:40 – 15:00	Genetic Subtyping of Dystonia *Schmidt*
15:00 – 15:20	Dystonia: From Genome to Proteome and Beyond *Warner*
15:20 – 15:40	Functional Neuroanatomy of Dystonia *Jinnah*
15:40 – 16:00	Neuroimaging of Dystonia *Delmaire*
16:00 – 16:30	Coffee Break

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Thursday, May 9th 2013

16:30 – 18:00	**Basic Research in Botulinum Toxins** *Johnson, Bigalke*
16:30 – 16:50	Botulinum Toxin Binding *Montecucco*
16:50 – 17:10	Central Nervous System Effects of Botulinum Toxin *Caleo*
17:10 – 17:30	Natural Diversity and Recombinant Technologies for New Botulinum Toxin Drugs *Foster*
17:30 – 17:50	Reducing Animal Consumption for Botulinum Toxin Drug Manufacturing *Johnson*
17:50 – 18:00	Free Oral Presentation
18:00 – 19:30	**Get Together**



Scientific Program

Friday, May 10th 2013

08:00 – 09:30	**Targets for Neuromodulation in Dystonia** *Moro, Krauss*
08:00 – 08:20	Globus Pallidus Internus *Krauss*
08:20 – 08:40	Thalamus and Subthalamicus *Timmermann*
08:40 – 09:00	Cortex *Franzini*
09:00 – 09:20	What happen to Low Frequency Stimulation? *Moro*
09:20 – 09:30	Free Oral Communication
09:30 – 10:00	Coffee Break
10:00 – 11:00	**Psychogenic Dystonia** *Hallett, Dressler*
10:00 – 10:20	Diagnosing Psychogenic Dystonia: Criteria and Assessment *Hallett*
10:20 – 10:40	Differential Diagnoses of Psychogenic Dystonia *Bhatia*
10:40 – 11:00	Treatment of Psychogenic Dystonia *Edwards*
11:15 – 12:00	**Special Lecture on Dystonia** *Altenmüller, Dressler, Krauss*
11:15 – 12:00	The Development of the Dystonia Concept *Fahn*
12:00 – 14:00	Lunch Break

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Friday, May 10th 2013

12:15 – 13:45	**Lunch Symposium** **Merz Pharmaceuticals**

14:00 – 16:00	**Special Topics in Surgical Treatment of Dystonia** *Lozano, Blahak*
14:00 – 14:20	Local Field Potentials in Dystonia *Kühn*
14:20 – 14:40	How does Deep Brain Stimulation work in Dystonia? *Quartarone*
14:40 – 15:00	The mysterious Time Course of the Response and Washout of DBS in Dystonia *Lozano*
15:00 – 15:20	Genetics do matter: Outcome of Deep Brain Stimulation *Altermann*
15:20 – 15:40	Deep Brain Stimulation for Cervical Dystonia: The German Multicentre Study *Volkmann*
15:40 – 16:00	Free Oral Presentation
16:00 – 16:30	Coffee Break

16:30 – 17:30	**Treatment of Musicians' Dystonias** *Frucht, Altenmüller*
16:30 – 16:50	Phenomenology of Musicians' Dystonia *Frucht*
16:50 – 17:10	Botulinum Toxin Therapy for Musicians' Dystonia *Pullman*
17:10 – 17:30	New Therapeutic Strategies in Musicians' Dystonia *Altenmüller*

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Friday, May 10th 2013

17:30 – 19:00	**Video Forum** *Lang, Sethi, Vidailhet*
20:00 – 23:00	**Gala Dinner**

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations.

NM-72410-AA8_JUN2012 Printed in Germany by medicalvision. © 2013 Boston Scientific Corporation or its affiliates. All rights reserved.

Scientific Program

Saturday, May 11th 2013

08:00 – 09:00	**Treatment of Dystonia in Children** *Fernandez-Alvarez, Sethi*
08:00 – 08:20	Strategies for Treatment of Dystonia in Children *Fernandez-Alvarez*
08:20 – 08:40	Deep Brain Stimulation in Children *Lin*
08:40 – 09:00	Botulinum Toxin for Treatment of Dystonia in Children *NN*
09:00 – 10:00	**Experimental Therapies of Dystonia** *Zeuner, Schwabe*
09:00 – 09:20	Animal Models in Dystonia *Pisani*
09:20 – 09:40	Treatment of Dystonia with Transcranial Electric and Magnetic Brain Stimulation *Ziemann*
09:40 – 10:00	Behavioural Therapies: What is new? What remains? *Zeuner*
10:00 – 10:30	Coffee Break



Scientific Program

Saturday, May 11th 2013

10:30 – 12:00	**Botulinum Toxin Therapy of Dystonia 1** *Kanovsky, Rosales*
10:30 – 10:50	Ultrasound Sonography to Improve Botulinum Toxin Therapy *Bäumer*
10:50 – 11:10	Advancing Botulinum Toxin Therapy: Increasing Doses, Reducing Intervals *Dressler*
11:10 – 11:30	Developing Botulinum Toxin A2 as a New Therapeutic Agent *Kaji*
11:30 – 11:50	Development Perspectives of Botulinum Toxin Drugs *Pickett*
11:50 – 12:00	Free Oral Communication
12:00 – 14:00	Lunch Break
12:15 – 13:00	**Lunch Symposium** **Ipsen Pharma**
13:00 – 13:45	**Lunch Symposium** **Medtronic Europe**

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Scientific Program

Saturday, May 11th 2013

14:00 – 15:00	**Botulinum Toxin Therapy 2** *Vidailhet, Colosimo*
14:00 – 14:20	Botulinum Toxin Therapy for Spasmodic Dysphonia *Blitzer*
14:20 – 14:40	Botulinum Toxin Therapy for Cranial Dystonia *Colosimo*
14:40 – 15:00	Treatment of Eye-Lid Opening Apraxia *Laskawi*
15:00 – 15:30	Coffee Break
15:30 – 16:30	**Oral Pharmacotherapy of Dystonia** *Moore, Comella*
15:30 – 15:50	Pharmacotherapy of Dystonia *Moore*
15:50 – 16:10	Measurement Instruments for Dystonia *Comella*
16:10 – 16:30	Treatment of Dystonic Tremor *Micheli*



Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.



Scientific Program

Saturday, May 11th 2013

16:30 – 17:50	**Rehabilitation, Prevention and Coping of Dystonia** *Wissel, Jabusch*
16:30 – 16:50	Rehabilitation of Dystonia *Wissel*
16:50 – 17:10	Novel Approaches in Rehabilitation of Musicians: DC-Stimulation Re-assessed *Furuya*
17:10 – 17:30	Prevention of Dystonia in Musicians *Jabusch*
17:30 – 17:50	Coping with Dystonia *Jabanshahi*
17:50 – 18:00	**Closing Remarks** *Altenmüller, Dressler, Krauss*

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

MORE CONTROL. LESS RISK.

St. Jude Medical is focused on reducing risk by continuously finding ways to put more control into the hands of those who save and enhance lives.

SJMneuropro.com

ST. JUDE MEDICAL™

ST. JUDE MEDICAL, the nine-squares symbol and MORE CONTROL. LESS RISK. are registered and unregistered trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2013 St. Jude Medical, Inc. All Rights Reserved.

Our Sponsors

Platinum

ALLERGAN

Gold

MERZ

Silver Premium

IPSEN
Innovation for patient care

Medtronic

Silver

ST. JUDE MEDICAL
MORE CONTROL. LESS RISK.

Bronze

Boston Scientific

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.

Special offer with Lufthansa

Lufthansa
Official Airline

Lufthansa German Airlines offers a comprehensive global route network linking Hannover with major cities around the world.

Participants of the Second International Congress on Treatment of Dystonia and their travel companions benefit from special fares and conditions in First, Business and Economy class.

To make your reservation, please use this Link:
www.lufthansa.com/event-booking_en

This will lead you to an online booking platform that will automatically calculate your discount.
Note: Pop-ups must be enabled. Otherwise the booking platform window will not open!

The booking code for this congress is: DEZSDFO



Imprint

Company:	INTERPLAN Congress, Meeting & Event Management AG
Place of business:	Landsberger Str. 155 80687 München Germany
Commercial Register:	Jurisdiction: Munich Registration Number: HRB 134 892
VAT Identification Number:	DE213274875
Contact:	Phone: +49-(0)89-548234-0 E-mail: info@interplan.de
Board of Directors:	Bruno Lichtinger, Dr. Markus Preußner, Dan Rivlin, Avi Rosner
Photos:	© Bea Busse - Fotolia.com, © Fantast - Fotolia.com © Michael Kügler - Fotolia.com, © Nils Volkmer - Fotolia.com © ReSeandra - Fotolia.com, © Thomas Aumann - Fotolia.com © guentermanaus - Fotolia.com

Please find all information concerning the congress at www.treatment-of-dystonia.org.
All information provided in this preliminary program is subject to change.